AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 272 min read$KIDS

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million…

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:

Original reporting
SEC EDGAR 8-K
Published Oct 27, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KIDS
Bullish
high confidence
Mentioned
$KIDS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KIDSBullishHigh
01

Why it matters

The raised guidance reflects strong growth in trauma, deformity, and scoliosis product lines, indicating expanding market share.

02

Market read

New guidance could trigger a short‑term rally in KIDS and influence related medical‑device peers.

03

What to watch

Potential supply‑chain constraints or reimbursement challenges for new pediatric devices.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

The filing is an SEC Form 8‑K Item 2.02 release, the first public disclosure of OrthoPediatrics' Q3 2026 performance and updated guidance.

Company-level read

Ticker impact

$KIDSBullishHigh confidence
Context

OrthoPediatrics reported Q3 2026 results with record revenue of $72.7M and raised full‑year 2026 revenue guidance to $270‑$273M.

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

The company beat prior quarter growth and increased guidance, which typically drives short‑term buying interest.

Market effects

Sector

Positive signal for the pediatric orthopedics and broader medical device sector.

Regional

May boost sentiment for US‑listed health‑care stocks in the Nasdaq composite.

Global

Limited to investors tracking niche medical device companies.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face a pull‑back once detailed product launch timelines are clarified.

Key entities

  • company
    OrthoPediatrics Corp.

    NASDAQ‑listed pediatric orthopedics device maker

Read at source← All news

Related articles

OCT 28
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com2 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com3 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics receives FDA clearance for femur nail system

OrthoPediatrics (KIDS) received FDA clearance for its Pediatric Nailing Platform Femur Retrograde Nail System, designed for pediatric trauma and deformity correction. The system is available in diameters from 7 mm to 11 mm and will be released in 2026, with broader commercialization in 2027. The company has used its Pediatric Nailing Platform in approximately 15,000 patients worldwide.

investing.com2 min
SEP 11
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

insidermonkey.com2 min
AUG 6
$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.

yahoo.com7 min
AUG 4
$KIDSMed

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-Year WARSAW, Ind., August 4, 2026 -- OrthoPediatrics Corp

SEC EDGAR 8-K6 min